Ausa Pharmaceutical

Shenzhen Ausa Pharmaceutical Co., Ltd. is a high-tech enterprise, a private enterprise in Nanshan District, Shenzhen, a headquarters enterprise in Nanshan District, and one of the top 100 taxpayers in Nanshan District for national tax. In 2019, it ranked 20th among the "Top 70 Innovative Enterprises in Shenzhen", and was honored as a "Pharmaceutical Industry Pride Enterprise" on the 70th anniversary of the founding of the People's Republic of China, and received the second prize of the National Science and Technology Progress Award. Ausa mainly targets cardiovascular and cerebrovascular diseases, researching and developing safe and effective diagnostic and therapeutic products, providing full lifecycle intelligent, digital, and precise health management software and hardware solutions from dietary nutrition supplementation, early disease detection, prevention to diagnosis, monitoring, and treatment. It adheres to the "dual-wheel drive" development strategy, with "artificial intelligence health big data as the engine, and the biomedical entity industry plus medical diagnosis and management service system jointly driving".
Professor Xu Xiping, a scientist at Ausa Pharmaceutical, has served as an associate professor at the Harvard School of Public Health and Harvard Medical School, and a professor at the School of Public Health of the University of Illinois. He is also a professor and doctoral supervisor at the National Clinical Research Center for Kidney Diseases of Southern Medical University, an editorial board member of "Progress in Pharmaceutical Sciences" and "Chinese Journal of New Drugs", and was ranked first in the medical field on the list of China's Highly Cited Researchers for two consecutive years in 2015 and 2016.